Delayed side effects after CAR-T for multiple myeloma
Part of Blood & lymphatic, Brain & nervous system, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at late side effects that may happen after CAR-T therapy (cilta-cel) for multiple myeloma. It aims to better understand these delayed toxicities so doctors can manage them more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with multiple myeloma and your doctor has planned for you to receive a standard CAR-T treatment called cilta-cel.
- You are willing to follow the study schedule and attend all visits.
- Your performance level is good enough to do most daily activities (ECOG score of 0, 1, or 2).
- You have not had CAR-T therapy or an allogeneic (donor) stem cell transplant before.
- You are not pregnant or breastfeeding, and have no active infections like hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time cell therapy called ciltacabtagene autoleucel (a CAR-T treatment) in people who have newly diagnosed multiple myeloma and are not eligible for a stem cell transplant. It aims to see if this treatment is safe and effective as an early therapy.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
This study tests an experimental cell therapy called CBG002 CAR-T for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses your own immune cells that are trained to find and attack myeloma cells with a protein called BCMA on their surface.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.